Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Biological Tumor Markers. Found 57 abstracts

no pagination
Barr PM, Miller TP, Friedberg JW, Peterson DR, Baran AM, Herr M, Spier CM, Cui H, Roe DJ, Persky DO, Casulo C, Littleton J, Schwartz M, Puvvada S, Landowski TH, Rimsza LM, Dorr RT, Fisher RI, Bernstein SH, Briehl MM. Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma. Blood. 2014 Aug 21;124(8):1259-65.   PMCID: Pmc4141515
Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM, Dalton WS, Gunchenko A, Cheng JD, Siu LL, Gray JE. A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Br J Cancer. 2014 Nov 11;111(10):1932-44.   PMCID: Pmc4229637
Keller LM, Galloway TJ, Holdbrook T, Ruth K, Yang D, Dubyk C, Flieder D, Lango MN, Mehra R, Burtness B, Ridge JA. p16 status, pathologic and clinical characteristics, biomolecular signature, and long-term outcomes in head and neck squamous cell carcinomas of unknown primary. Head & neck. 2014 Dec;36(12):1677-84.   PMCID: PMC3972378
Plimack ER, Hoffman-Censits J, Rosenberg JE, Wong YN, Bellmunt J, Choueiri TK. Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye [Letter]. J Clin Oncol. 2014 Dec 20;32(36):4171-2.
Psyrri A, Lee JW, Pectasides E, Vassilakopoulou M, Kosmidis EK, Burtness BA, Rimm DL, Wanebo HJ, Forastiere AA. Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303. Clin Cancer Res. 2014 Jun;20(11):3023-32.   PMCID: Pmc4049169
Loo L, Capobianco JA, Wu W, Gao X, Shih WY, Shih WH, Pourrezaei K, Robinson MK, Adams GP. Highly sensitive detection of HER2 extracellular domain in the serum of breast cancer patients by piezoelectric microcantilevers. Anal Chem. 2011 May;83(9):3392-7.   PMCID: PMC3084889
Bellacosa A, Godwin AK, Peri S, Devarajan K, Caretti E, Vanderveer L, Bove B, Slater C, Zhou Y, Daly M, Howard S, Campbell KS, Nicolas E, Yeung AT, Clapper ML, Crowell JA, Lynch HT, Ross E, Kopelovich L, Knudson AG. Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations. Cancer Prev Res (Phila Pa). 2010 Jan;3(1):48-61.   PMCID: PMC2804937
Xu XZ, Garcia MV, Li TY, Khor LY, Gajapathy RS, Spittle C, Weed S, Lessin SR, Wu H. Cytoskeleton alterations in melanoma: aberrant expression of cortactin, an actin-binding adapter protein, correlates with melanocytic tumor progression. Mod Pathol. 2010 Feb;23(2):187-96.   PMCID: PMC2827925
Dorgan JF, Stanczyk FZ, Egleston BL, Kahle LL, Shaw CM, Spittle CS, Godwin AK, Brinton LA. Prospective case-control study of serum mullerian inhibiting substance and breast cancer risk. Journal of the National Cancer Institute. 2009 Nov 04;101(21):1501-9.   PMCID: PMC2773186
Randall LM, Monk BJ, Darcy KM, Tian C, Burger RA, Liao SY, Peters WA, Stock RJ, Fruehauf JP. Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study. Gynecologic Oncology. 2009 Mar;112(3):583-9.   PMCID: PMC2858218
Schilder RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C, Min H, Devarajan K, Ross E, Drescher CW, Godwin AK. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol. 2009 Apr;113(1):21-7.   PMCID: PMC 2741166
Khor LY, Bae K, Al-Saleem T, Hammond EH, Grignon DJ, Sause WT, Pilepich MV, Okunieff PP, Sandler HM, Pollack A. Protein kinase A RI-alpha predicts for prostate cancer outcome: analysis of radiation therapy oncology group trial 86-10. Int J Radiat Oncol Biol Phys. 2008 Aug;71(5):1309-15.
Kosteva J, Langer C. The changing landscape of the medical management of skeletal metastases in nonsmall cell lung cancer. Curr Opin Oncol. 2008 Mar;20(2):155-61.
Small W, Berlin J, Freedman GM, Lawrence T, Talamonti MS, Mulcahy MF, Chakravarthy AB, Konski AA, Zalupski MM, Philip PA, Kinsella TJ, Merchant NB, Hoffman JP, Benson AB, Nicol S, Xu RM, Gill JF, McGinn CJ. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2008 Feb 20;26(6):942-7.
Wang Y, Ikeda DM, Narasimhan B, Longacre TA, Bleicher RJ, Pal S, Jackman RJ, Jeffrey SS. Estrogen receptor-negative invasive breast cancer: imaging features of tumors with and without human epidermal growth factor receptor type 2 overexpression. Radiology. 2008 Feb;246(2):367-75.
Crispen PL, Uzzo RG, Golovine K, Makhov P, Pollack A, Horwitz EM, Greenberg RE, Kolenko VM. Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemoprevention. The Prostate. 2007 May;67(6):582-90.
Denlinger CS, Cohen SJ. Progress in the development of prognostic and predictive markers for gastrointestinal malignancies. Current treatment options in oncology. 2007 Oct;8(5):339-51.
Giri VN, Beebe-Dimmer J, Buyyounouski M, Konski A, Feigenberg SJ, Uzzo RG, Hanks G, Godwin AK, Chen DY, Gordon R, Cescon T, Raysor S, Watkins-Bruner D. Prostate cancer risk assessment program: a 10-year update of cancer detection. J Urol. 2007 Nov;178(5):1920-4; discussion 1924.
Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, Allison DE, Eberhard DA, Pham TQ, Dere RC, Karlan BY. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol. 2006 Sep 10;24(26):4324-32.
Meropol NJ, Gold PJ, Diasio RB, Andria M, Dhami M, Godfrey T, Kovatich AJ, Lund KA, Mitchell E, Schwarting R. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.[see comment]. Journal of Clinical Oncology. 2006 Sep;24(25):4069-77.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Biological Tumor Markers

Biological Tumor Markers Female Middle Aged Male metabolism Adult Aged pathology 80 and over Aged blood drug therapy Disease-Free Survival analysis Neoplasm Staging adverse effects genetics mortality Prognosis Monoclonal Antibodies therapeutic use Antineoplastic Combined Chemotherapy Protocols administration & dosage Treatment Outcome erbB-2 Receptor methods Immunohistochemistry Neoplastic Gene Expression Regulation Antineoplastic Agents Breast Neoplasms Survival Analysis Tissue Array Analysis effects Prostatic Neoplasms therapy Neoplasm Proteins adverse Predictive Value of Tests radiotherapy chemistry Logistic Models aa [Analogs & Derivatives] Thymidylate Synthase dt [Drug Therapy] Thymidine Phosphorylase me [Metabolism] Case-Control Studies Cohort Studies Deoxycytidine immunology Proportional Hazards Models Proto-Oncogene Proteins c-akt Risk Assessment Age Factors Ovarian Neoplasms Fluorescent Antibody Technique diagnosis Follow-Up Studies chemically induced physiology Gene Expression Profiling Drug Dose-Response Relationship Squamous Cell Carcinoma Head and Neck Neoplasms Reverse Transcriptase Polymerase Chain Reaction Risk Factors Biological) 0 (Tumor Markers Drug Administration Schedule pa [Pathology] biosynthesis Intravenous Infusions pd [Pharmacology] EC 2-4-2-4 (Thymidine Phosphorylase) Odds Ratio 17407-37-3 (vitamin E succinate) Electricity 0 (NF-kappa B) Lactate Dehydrogenases Bone Neoplasms Mass Screening B-Cell Lymphoma Pennsylvania Lung Neoplasms Mutation Ovary classification Data Mining Uterine Cervical Neoplasms Cytoskeleton Melanoma Cystectomy EC 2-1-1-45 (Thymidylate Synthase) Skin Neoplasms drug Dimerization epidemiology Vascular Endothelial Growth Factor A Chemoradiotherapy Reproducibility of Results Transcription Factor AP-1 CA-19-9 Antigen Camptothecin Disease Progression surgery Vitamin E Nevus Neoplasm Circulating Cells Transitional Cell Carcinoma Non-US Gov't Research Support NF-kappa B Superoxide Dismutase IGF Type 1 Receptor Local Neoplasm Recurrence Microsatellite Instability Blood Chemical Analysis Blood Banks Granulocyte Colony-Stimulating Factor human papillomavirus (HPV) Non-Small-Cell Lung Carcinoma Oligonucleotide Array Sequence Analysis use Oxidative Stress Pancreatic Neoplasms Protective Agents ai [Antagonists & Inhibitors] Incidence dosage Propionates 951-77-9 (Deoxycytidine) Cell Adhesion Randomized Controlled Trials as Topic Missouri Premenopause Paclitaxel ras Proteins DNA-Binding Proteins Proteomics Prospective Studies Enzyme-Linked Immunosorbent Assay 0 (Neoplasm Proteins) Phosphatidylinositol 3-Kinases drug effects therapeutic Analysis of Variance Feasibility Studies EC 1-3-1-2 (Dihydrouracil Dehydrogenase (NADP)) Epidermal Growth Factor Receptor Unknown Primary Neoplasms TOR Serine-Threonine Kinases Phase III Clinical Trials as Topic Urinary Bladder Neoplasms
Last updated on Sunday, July 05, 2020